CD79A and COVID-19: Together, these data showed that patients with rheumatic diseases could have a robust humoral immune response towards COVID-19 mRNA vaccines after two doses, followed by a gradual decline and a strong recovery of anti-SARS-CoV-2 S1 IgG and IgA titers after a 3rd dose.